CD274 and non-small cell lung carcinoma: The few results from phase I and II clinical trials targeting the TIGIT/CD155 axis, mainly in advanced non-small-cell lung cancer (NSCLC) patients [41,42], have demonstrated the efficacy of combining anti-TIGIT mAbs (vibostolimab or tiragolumab) with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) mAbs, respectively.